SRRK Stock Analysis: Scholar Rock Holding | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 6.576m USD | 12M Return: 59.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 77.4M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, founded in 2012 and listed on NASDAQ under the ticker SRRK. The company is focused on developing monoclonal antibodies that selectively target the precursor (latent) forms of growth factors within the transforming growth factor beta (TGFß) superfamily, with an initial focus on rare, severe neuromuscular diseases such as spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD).
Its lead product candidate, Apitegromab, is a myostatin activation inhibitor currently in a Phase 2 clinical trial for SMA and FSHD. The pipeline also includes SRK-439, a second anti-pro/latent myostatin antibody in Phase 1 development; SRK-181, a Phase 2-ready latent TGFß1 inhibitor intended for solid tumors resistant to anti-PD-(L)1 therapies; and pre-clinical programs SRK-373 (targeting fibrotic diseases) and SRK-256 (an RGMc/hemojuvelin inhibitor for iron-restricted anemias).
As a mid-cap clinical-stage biotechnology company in the GICS Health Care sector, Scholar Rock is pre-commercial and therefore reliant on capital markets and partnerships to fund ongoing R&D, a typical model for orphan-disease and rare-disease developers pursuing high-value specialty indications.
- Apitegromab Phase 3 SAPPHIRE topline data in SMA
- FDA approval and commercial launch of apitegromab
- Cash runway and potential dilutive financing risk
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.61 > 0.02 and ΔFCF/TA -6.91 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.57 > 3% & CFO -303.5m > Net Income -408.7m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.64 > 1.5 & < 3 |
| Outstanding Shares: last quarter (127.3m) vs 12m ago 13.80% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -54.41 > 6 (EBIT TTM -401.4m / Interest Expense TTM 7.38m) |
| A: 0.85 (Total Current Assets 515.3m - Total Current Liabilities 59.6m) / Total Assets 535.3m |
| B: -2.63 (Retained Earnings -1.41b / Total Assets 535.3m) |
| C: -0.85 (EBIT TTM -401.4m / Avg Total Assets 471.4m) |
| D: 1.06 (Book Value of Equity 276.0m / Total Liabilities 259.2m) |
| Altman-Z'' = -7.58 = D |
As of July 08, 2026, the stock is trading at USD 56.56 with a total of 1,115,887 shares traded. Over the past week, the price has changed by +2.91%, over one month by +29.13%, over three months by +13.35% and over the past year by +59.41%.
Current recommended Stop Loss: 53.80 (which is 4.9% or 1.2 ATR below the current price).
Scholar Rock Holding has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy SRRK.
- StrongBuy: 6
- Buy: 4
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 59.3 | 4.9% |
P/S = 13.1358
P/B = 22.94
Revenue TTM = 0.0 USD
EBIT TTM = -401.4m USD
EBITDA TTM = -399.8m USD
Long Term Debt = 196.6m USD (from longTermDebt, last quarter)
Short Term Debt = 6.08m USD (from shortTermDebt, last quarter)
Debt = 214.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 9.06m
Net Debt = -265.2m USD (calculated: Debt 214.7m - CCE 479.9m)
Enterprise Value = 6.31b USD (6.58b + Debt 214.7m - CCE 479.9m)
Interest Coverage Ratio = -54.41 (Ebit TTM -401.4m / Interest Expense TTM 7.38m)
EV/FCF = -19.29x (Enterprise Value 6.31b / FCF TTM -327.1m)
FCF Yield = -5.18% (FCF TTM -327.1m / Enterprise Value 6.31b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 51.7m) / Revenue TTM)
Tobins Q-Ratio = 11.79 (Enterprise Value 6.31b / Total Assets 535.3m)
Interest Expense / Debt = 3.43% (Interest Expense 7.38m / Debt 214.7m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -317.1m (EBIT -401.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.48 (Total Current Assets 515.3m / Total Current Liabilities 68.9m)
Debt / Equity = 0.78 (Debt 214.7m / totalStockholderEquity, last quarter 276.0m)
Debt / EBITDA = 0.66 (negative EBITDA) (Net Debt -265.2m / EBITDA -399.8m)
Debt / FCF = 0.81 (negative FCF - burning cash) (Net Debt -265.2m / FCF TTM -327.1m)
Total Stockholder Equity = 249.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -86.70% (Net Income -408.7m / Total Assets 535.3m)
RoE = -163.5% (Net Income TTM -408.7m / Total Stockholder Equity 249.9m)
RoCE = -89.88% (EBIT -401.4m / Capital Employed (Equity 249.9m + L.T.Debt 196.6m))
RoIC = -65.82% (negative operating profit) (NOPAT -317.1m / Invested Capital 481.7m)
WACC = 11.09% (E(6.58b)/V(6.79b) * Re(11.36%) + D(214.7m)/V(6.79b) * Rd(3.43%) * (1-Tc(0.21)))
Discount Rate = 11.36% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 25.77%
[DCF] Fair Price = unknown (Cash Flow -327.1m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.45 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.84 | Chg30d=+0.00% | Revisions=+0% | Analysts=11
EPS next Quarter (2026-09-30): EPS=-0.86 | Chg30d=+0.00% | Revisions=-15% | Analysts=14
EPS current Year (2026-12-31): EPS=-3.07 | Chg30d=+0.00% | Revisions=-10% | GrowthEPS=+6.7% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-2.55 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=+19.7% | GrowthRev=+2195.3%
[Analyst] Revisions Ratio: -27% (up=12, down=22)